Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP05
- Development stage
- Unknown
- Lead developer
- Aprogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AP05 is a rituximab biosimilar monoclonal antibody being developed by Aprogen, a South Korean biopharmaceutical company. It is a chimeric monoclonal antibody designed to target CD20, a cell surface protein predominantly expressed on B lymphocytes. As a biosimilar to the reference drug Rituxan (rituximab), AP05 functions as a B-cell depleting agent. Its mechanism of action involves binding to CD20 and inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The drug is currently in Phase I clinical development for the treatment of lymphoma, with the goal of providing a more affordable therapeutic option while maintaining the efficacy and safety profile of the original biologic.
- Other names
- rituximab biosimilarAprogen rituximab biosimilar
02
Targets
Beyond the preview
Go deeper on AP05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP05.